Cancer treatment has improved greatly over the years, but understanding how well treatments work is still a challenge. This is especially true for patients whose cancer has spread to a few areas in the body, a condition known as oligometastatic cancer.
This stage sits between early cancer and widely spread disease. At this point, treatment can still be very effective, and some patients may even achieve long-term survival.
A new international effort led by researchers from MedUni Vienna and University Hospital Vienna is changing how doctors measure treatment success for these patients. Their findings, published in The Lancet Oncology, suggest that traditional ways of measuring results may not fully reflect what patients go through during treatment.
The study focused on modern treatments that directly target metastases. These treatments, known as metastasis-directed therapies, include advanced radiotherapy techniques, surgery, and heat-based treatments. They are designed to remove or destroy small tumors with great precision, often using detailed imaging to guide the process.
The research team used data from the OligoCare study, which followed more than 3,500 patients across different types of cancer. This large dataset allowed experts from different fields, including doctors, researchers, and patient representatives, to work together and agree on better ways to measure outcomes.
Traditionally, researchers have relied on progression-free survival to judge treatment success. This method looks at how long it takes before the cancer grows or spreads. While useful, it does not fully capture the benefits of treatments that can repeatedly remove small metastases and delay more aggressive therapies.
To improve this, the team introduced two new measures. The first is STFS, which measures how long patients can avoid starting or changing major drug treatments. The second is pPFS, which measures how long it takes before the cancer spreads widely throughout the body.
These new measures focus more on the patient’s experience. Many patients value the ability to delay strong treatments and maintain a good quality of life. The new approach also reflects the fact that doctors can treat metastases multiple times, rather than viewing cancer progression as a single event.
This change represents a new direction in cancer research. By focusing on outcomes that matter to patients, studies can provide more meaningful results. This may also help bring new treatments into clinical practice more quickly.
However, the researchers caution that these new measures still need further testing. Future clinical trials will be needed to confirm their value and to see how they relate to long-term outcomes like survival.
Overall, this study highlights the importance of looking beyond traditional measures when evaluating cancer treatments. It shows that precise therapies can offer real benefits, especially when assessed in ways that reflect daily life.
The findings encourage a more personalized approach to cancer care, where treatment decisions are based not only on disease control but also on quality of life.
If you care about cancer, please read studies that low-carb diet could increase overall cancer risk, and new way to increase the longevity of cancer survivors.
For more health information, please see recent studies about how to fight cancer with these anti-cancer superfoods, and results showing daily vitamin D3 supplementation may reduce cancer death risk.
Source: MedUni Vienna.
